Symbol | Exchange | Currency |
|---|
RAMSEY, N.J. and BOCA RATON, Fla., June 14, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (the "Company"), an end-to-end commercial biopharmaceutical company...
RAMSEY, N.J. and BOCA RATON, Fla., May 26, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (the "Company"), an end-to-end commercial biopharmaceutical company...
ADMA Biologics (ADMA) shares rise more than5%during post-market trading after the company reported first-quarter results that beat Wall Street estimates, helped by thecontinued...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Sell | Sell | Strong Sell | Strong Sell |
| Technical Indicators | Buy | Buy | Neutral | Buy | Strong Sell |
| Summary | Buy | Neutral | Neutral | Neutral | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 336.51 | 337.98 | 330.15 | +5.43 | +1.64% | 17.79M | NASDAQ | |||
| 2,434.87 | 2,450.45 | 2,410.00 | +19.42 | +0.80% | 1.29M | NASDAQ | |||
| 60.73 | 63.83 | 52.98 | +5.55 | +10.06% | 302.87M | NYSE | |||
| 209.45 | 218.27 | 207.88 | -7.71 | -3.55% | 7.99M | NYSE | |||
| 211.60 | 212.49 | 209.77 | +2.28 | +1.09% | 11.23M | NYSE | |||
| 28.74 | 29.15 | 28.71 | -0.32 | -1.10% | 35.69M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 16.40 | 17.40 | 16.16 | -1.40 | -7.87% | 12.52M | NYSE | |||
| 56.53 | 56.92 | 56.50 | -0.11 | -0.19% | 14.76M | NYSE | |||
| 1.39 | 1.46 | 1.33 | -0.1100 | -7.33% | 19.61M | NYSE | |||
| 24.01 | 25.08 | 23.61 | -1.15 | -4.57% | 8.67M | NYSE | |||
| 0.6731 | 0.00 | 0.00 | -0.0229 | -3.29% | 3.19M | NYSE | |||
| 6.68 | 6.89 | 6.60 | -0.43 | -6.05% | 30.19M | NYSE | |||
| 64.43 | 66.12 | 64.38 | -3.99 | -5.83% | 2.23M | NYSE | |||
| 34.30 | 35.92 | 33.75 | +0.100 | +0.29% | 10.12M | NASDAQ |
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
